Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Emerging disease modifying therapies for multiple sclerosis.

Emmanuelle Waubant1

  • 1UCSF MS Center, 350 Parnassus Street, Suite 908, San Francisco, CA 94117, USA. waubant@itsa.ucsf.edu

Expert Opinion on Emerging Drugs
|November 13, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Application of the 2024 McDonald Criteria in Individuals With Nonspecific Symptoms or Incidental Imaging Findings in a Multicenter Study.

Neurology·2026
Same author

High-dose <i>N</i>-acetyl cysteine reduces GFAP levels: Exploratory results from a pilot double-blind, placebo-controlled randomized trial.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Adenotonsillectomy is associated with increased risk and disease activity in pediatric-onset multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

The gut microbiome in pediatric-onset acquired demyelinating syndromes by myelin oligodendrocyte glycoprotein antibody status.

Multiple sclerosis and related disorders·2026
Same author

Higher ultra-processed food consumption is associated with higher likelihood of paediatric-onset multiple sclerosis.

Multiple sclerosis and related disorders·2026
Same author

Accelerated metabolomic aging and its association with social determinants of health in multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

Multiple sclerosis (MS) is a CNS demyelinating disease influenced by genetics and environment. New therapies are being developed to improve treatment efficacy and reduce side effects.

Area of Science:

  • Neuroimmunology
  • Central Nervous System (CNS) Disorders

Background:

  • Multiple sclerosis (MS) is the most common CNS demyelinating disease.
  • Its etiology involves genetic and environmental factors, often affecting young adults.
  • Current treatments for MS are partially effective, parenterally administered, and have side effects.

Purpose of the Study:

  • To review the current landscape of multiple sclerosis (MS) therapies.
  • To highlight the limitations of existing treatments for MS.
  • To discuss emerging therapeutic strategies for MS.

Main Methods:

  • Literature review of MS pathogenesis and treatment.
  • Analysis of current disease-modifying therapies for MS.
  • Overview of novel therapeutic targets in MS research.

Related Experiment Videos

Main Results:

  • Existing MS therapies offer partial efficacy with significant side effects.
  • New therapies aim to improve immunosuppression, immunomodulation, and neuroprotection.
  • Targeting cell traffic across the blood-brain barrier (BBB) and CNS repair are key areas.

Conclusions:

  • There is a critical need for more effective and safer MS treatments.
  • Emerging therapies hold promise for addressing unmet needs in MS management.
  • Future research focuses on comprehensive strategies including repair and neuroprotection.